600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical ... - Reuters

600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical ... Reuters Today the development of tasquinimod is principally focused on the treatment of prostate cancer. It was announced in December 2009 that the primary endpoint of the Phase II clinical study, to show a higher fraction of patients with no disease ... ACTIVE BIOTECH AB : 600 Patients Recruited in Active Biotech's and Ipsen's ...4-traders Active Biotech, Ipsen reach €10m milestone in Phase III study of tasquinimodPharmaceutical Business Review Ipsen, Active Biotech Say 600 Patients Recruited In Phase 3 Tasquinimod StudyNASDAQ all 20 news articles »

Cancer doctors put competition aside to share treatment options for their patients - Washington Post

Cancer doctors put competition aside to share treatment options for their patients Washington Post Over an informal dinner in a Chevy Chase home, 25 doctors peppered one another with questions about prostate cancer treatments and clinical trials. By the end of the meal they had received a real-time, one-stop update. Several promised to refer their ...